As the central component of the complement system, C3 has sensory and effector functions bridging innate and adaptive immunity. It is plausible that common genetic variation at C3 determines either serum C3 level or susceptibility to systemic lupus erythematosus (SLE), but only a single, Japanese, study has currently showed genetic association. In a cohort of 1371 individuals from 393 UK white European SLE families, we quantified serum C3 and genotyped C3 tagSNPs. Using a Bayesian variance components model, we estimated 39.6% serum C3 heritability. Genotype/serum C3 association was determined by mixed linear models. Single nucleotide polymorphism (SNP) rs344555, located in a haplotype block incorporating the 3 0 end of C3, was associated with serum C3 (P ¼ 0.007), with weaker associations observed for other SNPs in this block. In an extended cohort of 585 SLE families the association between C3 variants and SLE was assessed by transmission disequilibrium test. SNP rs3745568 was associated with SLE (P ¼ 0.0046), but not with serum C3. Our disease associated SNP differs from that highlighted in the Japanese study; however, we replicate their finding that genetic variants at the 3 0 end of C3 are associated with serum C3. Larger studies and further fine mapping will be required to definitively identify functional variants.
Introduction
Activation of any of the complement pathways leads to proteolytic cleavage of C3. The C3 cleavage fragments have diverse biological activity including the chemoattraction of inflammatory cells, a lowering of B-cell activation thresholds and the opsonization of altered cells and immune complexes. C3 therefore has pivotal sensory and effector functions that bridge both innate and adaptive immunity. 1 Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies primarily directed against ubiquitous nuclear antigens. The 'waste-disposal' hypothesis proposes that this abnormal immune response is because of a failure of the physiological mechanism by which debris from apoptotic cells are cleared in a non-inflammatory manner. 2, 3 The classical complement pathway is known to play an important role in this process. 4 In addition, complement is critical for the opsonization and clearance of autoantibody containing immune complexes. 5, 6 Complement abnormalities may therefore play a role in both the initiation of SLE and in the ongoing tissue damage caused by immune complex deposition.
The demonstration of familial clustering of SLE cases provides evidence for a strong genetic component to disease susceptibility, although a complex interaction of genetic and environmental factors is likely to determine whether disease actually develops. 7 The observation that individuals with complete deficiency in early components of the classical complement cascade (most notably C1q) commonly develop lupus-like disease again highlights a critical role for this pathway in disease pathogenesis. 8 The association between C4 null alleles and SLE is also well described, although it remains to be definitively determined whether this effect is truly independent from effects observed because of linkage disequilibrium with associated HLADR alleles. 9, 10 The most comprehensive review to date reports SLE-type autoimmune manifestations (most commonly a rash) in 26% of patients with complete C3 deficiency. 11 It should be noted that the majority of these patients do not develop full-blown SLE, and also, although complete deficiencies are highly penetrant, they are also exceptionally rare, and will not contribute to SLE pathogenesis in the majority of cases. Nonetheless, the identification of these patients does highlight that C3, along with the other complement component genes, are worthwhile candidates for the identification of common variants associated with sporadic SLE. For C3, there is only a single study in a Japanese population (odds ratio 1.40). 12 This study also found, in a small cohort of patients with SLE, that this variant was also associated with C3 levels, suggesting that disease susceptibility may be influenced by genetically determined variation in serum C3. We have earlier reported that serum C3 level is a heritable trait, even in individuals who do not have SLE, but currently no studies have comprehensively mapped the C3 gene for cis-acting variants, which influence C3 expression. 13 The aim of the work presented in this paper was to replicate our earlier report of C3 heritability in an independent cohort of SLE families. Using a tagSNP approach, we sought to identify the genetic variants accounting for this heritability. Finally, we examined the association between C3 variation and SLE susceptibility in our large cohort of UK SLE families.
Results

Serum C3-heritability
The mean age of individuals from the 393 families with serum C3 data was 53.9 years (standard deviation 16.5), and of them 33.7% were male. The mean serum C3 was 1054 mg l À1 (range 294-1564 mg l
À1
). Table 1 shows the influence of age, sex and SLE affection on serum C3, assessed using both maximum likelihood and Bayesian methodologies. As expected, serum C3 was significantly lower in SLE probands; it was also lower in male participants and increased marginally with age.
In a Bayesian variance components model of serum C3, adjusted for SLE affection, age and sex, we estimated C3 heritability to be 39.6% (h 2 ¼ 0.396, 95% Credible Interval 0.250, 0.565). This estimate of heritability was robust to a range of prior assumptions in the model, not changing by an appreciable extent.
Serum C3-genetic associations
The 14 C3 tagSNPs all passed quality control checks and single nucleotide polymorphism (SNP) information is presented in Table 2 . It was noted that rs344540 and rs344542 were in tight linkage disequilibrium (LD) (r 2 ¼ 0.998); therefore, rs344542 was dropped from further analysis, leaving 13 SNPs for association testing. Strong association was observed between serum C3 levels and SNP rs344555, with additional weaker associations also seen with SNPs rs2277984, rs7951 and rs423490 (data presented in Table 3 ). In particular, the rare allele of rs344555 was associated with higher serum C3 levels in both maximum likelihood and Bayesian models. This association remained significant at Po0.05 even after applying a Bonferroni correction adjusted for the correlation between markers (13 SNPs mean r 2 ¼ 0.2704). A global w 2 of association for all SNPs was also significant (P ¼ 0.026).
As outlined in the methods section, we also carried out a post hoc analysis of the existing genotype data for IL6 and IL1B. No association was observed for the IL6 genotypes, but a borderline association was seen between serum C3 and two SNPs in IL1B, rs7596461 and rs1143634. These data are presented in Table 4 . Serum C3-haplotype structure Figure 1 shows the LD structure of the typed C3 SNPs in this cohort. It can be seen that rs344555, the key SNP associated with serum C3 level, forms part of a four-SNP haplotype encompassing the 3 0 end of the gene downstream of intron 29. Also incorporated in this haplotype are rs7951 and rs2277984, both of which showed weak association with serum C3, with the rare alleles associated with lower serum C3 (Table 1) .
SLE-C3 genetic associations
C3-imputation analysis
To determine whether we had found the most likely causal variant at C3 in our UK SLE family cohort, we undertook an imputation analysis on the basis of European HapMap data. Using the software package, BEAGLE (see Patients and methods), which has the capability of using family data, we imputed 287 SNPs across a 300-kb interval incorporating the C3 locus. None of the imputed SNPs were associated with SLE (P40.1), although rs3745568 remained significant (P ¼ 0.0045) with the C allele under transmitted.
Discussion
The data presented in this paper confirm that serum C3 is a heritable trait, using an independent cohort, and an alternative statistical methodology to our earlier study. 13 The Bayesian approach we adopted had the advantage of allowing us to test the sensitivity of the estimate for different prior assumptions regarding heritability in these nuclear families. Having confirmed that there is a C3 genetics in SLE families B Rhodes et al significant genetic component to serum C3 variation, we identified cis-acting genetic variants that accounted, in part, for this effect. Finally, we also confirmed that genetic variation within C3 is associated with susceptibility to SLE. The strongest association with serum C3 was observed for SNP rs344555, located in intron 37. The rare allele of this SNP was associated with higher level of serum C3, even after correction for the testing of multiple hypotheses. Haplotype analysis showed that rs344555 was located in a distinct haplotype block, along with rs2277984, rs7951 and rs344550. The rare alleles of rs344555, rs2277984 and rs7951 each defined a distinct haplotype, with two additional haplotypes delineated by the rare allele of rs344550. SNP rs344555 therefore defined a haplotype associated with higher serum C3. SNPs rs2277984 and rs7471, and the haplotypes they defined, were associated with lower serum C3, albeit with lower levels of significance.
Our haplotype tagging strategy should ensure that all common genetic variation at C3 has been captured. A disadvantage of this approach, however, is that there remains uncertainty over the identity of truly functional alleles (which may not have been genotyped or even identified). By reference to the pattern of LD observed both in our own data and in the data from the HapMap CEPH panel, it is possible, however, to make some broad statements about where the functional variant is likely to lie. There is very weak LD between the key variant rs344555 and SNPs in the C3 promoter or proximal coding sequence. There is a moderate LD between rs344555 and sporadic SNPs in the downstream gene, TNFSF14, but it seems unlikely that these SNPs alter serum C3 levels. Most likely, therefore, is that serum C3 is influenced by genetic variation in the distal end of C3. As no amino acid coding changes have been identified in this region, it is likely that the variant alters serum C3 levels by an effect on the stability or trafficking of C3 mRNA.
Our estimate of 39.6% heritability for serum C3 is similar to that reported for other acute phase plasma proteins such as C-reactive protein and fibrinogen. [14] [15] [16] It is also similar to our earlier estimate made in an independent cohort of healthy white European individuals (37.8%), suggesting that the generic 'SLE' term included as a covariate in our association models was adequate to account for the effect of disease status on serum C3 levels. 13 It is interesting that the incorporation of rs344555 genotype as a covariate in our variance components model resulted in only a negligible change to the overall heritability estimate (data not shown), suggesting that the key genetic effects accounting for C3 variability arise from trans-acting loci and currently remain unaccounted for. As serum C3 level in healthy individuals will be determined both by the rate of C3 synthesis and by the rate of low-level complement turnover, it is possible that variation in a large number of genes may account for the observed heritability. These may include acute-phase cytokine genes, early complement component genes or complement regulatory factor genes. We were unable to identify a clear association between serum C3 and the well-described IL6 and IL1B variants we tested, although it should be noted that these SNPs do not constitute a comprehensive screen of either of these loci.
A different variant accounted for the effect on SLE susceptibility. The disease-associated SNP, rs3745568, was located in a haplotype block encompassing the central region of C3 (between intron 22 and intron 29). Our imputation analysis failed to identify a stronger disease association in an extensive array of 287 known SNPs in and around C3, whereas no association was observed with the directly genotyped rs2230199, encoding the C3F/C3S structural variant. It is interesting that no association was observed between rs3745568 and serum C3, and there is no evidence from the HapMap CEPH panel of longer range LD between this SNP and the downstream gene TNFSF14. The mechanism underlying the association between this SNP (or variants in LD with it) and SLE therefore remains uncertain but, from our data, it does not seem to be a result of genetically determined alteration in serum C3 level. Whereas the mechanism of this association remains uncertain, it should be noted that a similar genetic interval, incorporating intron 27, has also been associated with bronchial asthma, adding additional weight to our argument that non-coding variation in the central region of C3 is a true disease susceptibility effect. 17 It is important to compare our results with the only other study, in a Japanese population, to also report association between C3 polymorphisms and both serum C3 and SLE. 10 There are notable differences between the variants found to be associated with SLE. The key SLE-associated SNP in the Japanese population was rs7951, which we tested, but found no disease association. Conversely, we observed an SLE association with rs3745568, which was not tested in the Japanese study, but with reference to the HapMap Japanese panel it does not seem to be in strong LD with either rs7951 or any other variant typed by these authors. One explanation for this difference is that neither has typed the true functional variant, and that differing patterns of LD across the locus in these ethnically diverse populations explain differences in observed indirect associations. Alternatively, our study simply lacked power to identify an association with rs7951, which was present at slightly lower frequency in our white European population. Assuming a disease odds ratio of 1.40, as determined in the Japanese study, a power calculation suggests that a family-based association study of our size would have only 30% power to detect an association at Po0.01. It also possible that all present findings, although plausible, may be false-positives, and future larger studies, with detailed fine mapping, may help inform on this issue.
In contrast to disease associations, similar associations were observed between C3 variants and serum C3 in the two populations. In the Japanese population an association between rs7951 and serum C3 was observed in a cohort of 87 SLE probands, leading to the hypothesis that disease susceptibility is increased by a variant that also leads to lower serum C3 levels. Like this study, we also observed a weak association with rs7951, although our key association was seen with rs344555, which was not typed in the Japanese study. Our data suggest that, in a white European population, distinct high and low C3-associated haplotypes within this block are tagged by rs344555 and rs7951, respectively. By reference to the HapMap Japanese population it seems that the LD structure in this region of the gene is rather different from ours, with no notable LD between rs7951 and rs344555. Once again it is likely that the true functional SNP remains to be identified, but both studies highlight the 3 0 end of the gene as the probable location for this variant.
Before the genetic associations we identify in this paper can be considered definitive, it will be necessary to replicate the findings in additional cohorts of individuals of similar ethnicity. Nonetheless, the similarities we have discussed between our data and the existing Japanese studies suggest that further detailed exploration of C3 genetics may be an interesting area for further research.
Patients and methods
Study cohort C3 heritability and the association of genotype with serum C3 was carried out in a cohort of 1371 individuals from 393 UK Caucasian SLE families, constituting an independent cohort from which we have earlier studied in relation to C3 heritability. 13 Data were available for 598 parents and 773 offspring (mean 1.49 siblings per family). The association of C3 genotype with SLE was studied in an extended cohort of 2211 individuals from 585 UK Caucasian SLE families (418 parent/proband trios and 167 additional families (either parent, proband and sibling or proband and multiple siblings)). All families were recruited through UK rheumatology clinics or by direct patient contact after media publicity. Ethical approval was obtained (MREC/98/2/6) and all participants gave appropriate informed consent. Each proband met ACR 1982 revised criteria for diagnosis. 18 Clinical data and sera were collected at a single time-point at study enrollment. Disease phenotype varied, but data collection took place in an outpatient setting from patients who were not 'acutely unwell'.
SNP selection and genotyping
A tagSNP approach to genotyping was employed, to ensure comprehensive genetic coverage across the C3 gene. The Tagger facility of Haploview (using an r 2 ¼ 0.8 threshold) was used to select tagSNPs that define the C3 haplotype blocks determined from the ethnically similar HapMap CEPH panel (http://www.hapmap.org/). 19, 20 In addition, we typed SNP rs2230199, which determines the well-described C3F and C3S structural variants. Genotyping was by Matrix-Assisted Laser Desorption and Ionization-Time of Flight (MALDI-TOF) mass spectrometry (Sequenom, Hamburg, Germany), using the iPLEX Gold protocol. 21 Using predefined quality control exclusions, we excluded any marker genotyping in o90% individuals, with a minor allele frequency o5% and out of Hardy-Weinberg equilibrium (Po0.01 calculated by w 2 in the subset of unaffected population founders). In addition, we excluded any individual with successful genotyping at o80% of markers, or with 410% of markers showing Mendelian error on Pedcheck. 22 Detailed C3 marker information is presented in Table 2 . In addition to this new genotyping, we also analyzed existing genotyping of four IL1B SNPs (rs16944, rs1143634, rs7596461 and rs4849124) and five IL6 SNPs (rs1800796, rs1800795, rs2069837, rs2069837 and rs1554606). Details on the genotyping of these markers may be found elsewhere.
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C3 Quantification Serum C3 was quantified by radial immunodiffusion assay using the Mancini method. 23 Plate to plate consistency was confirmed by the consistent use of low and high C3 control samples. No plates departed from the normal distribution expected because of standard measurement error (P ¼ 0.20 by KologorovSmirnov test).
Statistical analysis
Data was stored and managed using BC/GENE v2.2.5 software (Biocomputing Platforms Ltd, Espoo, Finland). Serum C3 heritability was estimated by Bayesian variance components modeling using WinBUGS v 1.4.3. 24, 25 Standardized age (mean age 53.9, s.d. ¼ 16.5), sex and SLE affection status were incorporated as covariates and variance components were modeled for additive genetic effect (Vu), common family effect (Vf) and common sibling environment (Vs). A weakly informative prior distribution was specified for the within-family correlations (half normal (0, 0.10) distribution). This was felt to be more appropriate than a noninformative prior distribution, as family members are obviously correlated to some extent, although it would be inappropriate to give equal weight to all levels of correlation. We also tested sensitivity to different prior distributions for variance components by running the same models with a g (2, 2) distribution, and different shapes of half normal distributions (0, 0.25) and (0, 0.4). The results did not change to any appreciable extent.
For the analysis of association of genotype with serum C3, a dual Bayesian/maximum likelihood analysis is presented. Bayesian analyses were again carried out using WinBUGs, whereas maximum likelihood models were carried out using STATA v.10 (StataCorp LP, College Station, TX, USA). For both approaches standardized age (as above), sex and SLE affection were incorporated as covariates in a linear regression model. A standardized normal (0, 1) distribution was specified as an earlier distribution for the model parameters. The Monte Carlo errors were o0.001. For the maximum likelihood analysis, a random factor was introduced to allow for family effects, but this was not broken down further into variance components. In the Bayesian analysis, variance components were also modeled as outlined for the heritability estimate.
The analysis of genetic association with SLE was carried out by transmission disequilibrium test using TRANSMIT. 26 We used BEAGLE 3.0 27, 28 to impute missing genotype calls and untyped genotypes over the range Chr19:6,500,000-6,800,000, which covered 287 SNPs. BEAGLE 3.0 uses a haplotype clustering algorithm and applies a Hidden Markov Model (HMM) approach to infer missing genotypes. After imputation, an allelic test (Fisher's exact test on the 2-by-2 table of transmitted/ untransmitted alleles) was carried out on every SNP using BEAGLE. 29 particular, we thank Peter Norsworthy for his assistance with the C3 radial immunodiffusion assays. This work was funded by the Arthritis Research Campaign Clinical Research Fellowship (B Rhodes) and the Wellcome Trust Senior Fellowship (TJ Vyse). We are grateful for support from the NIHR Biomedical Research Centre funding scheme and for the NIH support P01 AI065687-03.
